BIO 2020 Notebook: Fauci On Price Controls; Biotech's Financing Advantage; Progress Towards Universal Flu Vaccine
News and views from day two of BIO Digital include Jim Greenwood on the prospects for drug development legislation.
You may also be interested in...
Cidara partners its antiviral conjugate platform for seasonal and pandemic influenza with Janssen, which also gets option rights to an AVC candidate for respiratory syncytial virus.
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
The company already has more than 20 subsidiaries developing treatments for monogenic diseases and genetically defined cancers, but its deal-making pace has not slowed.